PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

Interest in PET/CT Whole-body Dynamic Acquisition at FDG to Differentiate Progression/Pseudo Progression of Metastatic Melanoma Under Immunotherapy

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..

Inclusion Criteria:

• Patient old ≥ 18 years
• With metastatic melanoma
• Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
• Having formulated a non-opposition

Exclusion Criteria:

• - Minor patient < 18 years
• Pregnancy or breastfeeding
• Other type of tumor than metastatic melanoma
• Non-eligibility for the examination
• Refusal of participation